Immunotherapy boost may help rectal cancer patients avoid surgery
NCT ID NCT06312982
First seen Jan 13, 2026 · Last updated May 12, 2026 · Updated 14 times
Summary
This study tests whether adding the immunotherapy drug tislelizumab to standard chemoradiation can improve outcomes for people with locally advanced rectal cancer. About 375 adults will receive either chemoradiation alone or combined with tislelizumab before surgery. The goal is to see if the combination leads to more complete tumor responses and helps more patients keep their rectum.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED RECTAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Friendship Hospital
RECRUITINGBeijing, Beijing Municipality, 100050, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Beijing Friendship Hospital, Capital Medical University
RECRUITINGBeijing, Beijing Municipality, 100050, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.